Merck shares fall 1.5% after $400 million cancer-drug deal
AI Summary- Merck agreed to worldwide rights for SciBrunch Therapeutics' SPR2015 cancer treatment.
- $400 million is payable upfront within a potential $2.13 billion deal.
- SPR2015 has not entered human testing as Merck faces Keytruda patent expirations later this decade.